Alsahaf M H, Stockwell M
Anaesthetic Department, St. Helier Hospital NHS Trust, Carshalton, Surrey, United Kingdom.
J Pain Symptom Manage. 2000 Sep;20(3):210-3. doi: 10.1016/s0885-3924(00)00173-1.
The transdermal therapeutic system (TTS) fentanyl has been designed for rate-controlled drug delivery. When the system is applied, a fentanyl depot concentrates in the upper skin layers. Plasma concentrations are not measurable until 2 hours after application, and it takes an 8-16 hr latency period until full clinical fentany effects are observed. Following removal, serum fentanyl concentrations decline gradually and fall to about 50% in approximately 16 hours. We report the case of a 77-year-old man with a history of severe arthritis, who was receiving transdermal fentanyl and developed respiratory failure after starting epidural diamorphine/bupivacaine for postoperative pain relief following radical nephrectomy.
透皮治疗系统(TTS)芬太尼是为控速给药而设计的。当该系统应用后,芬太尼储库会集中在上皮层。用药后2小时内血浆浓度无法测得,直到8 - 16小时的潜伏期后才能观察到芬太尼的完全临床效果。取下该系统后,血清芬太尼浓度逐渐下降,约16小时后降至约50%。我们报告一例77岁男性患者,有严重关节炎病史,正在接受透皮芬太尼治疗,在根治性肾切除术后开始使用硬膜外二醋吗啡/布比卡因缓解术后疼痛后出现呼吸衰竭。